Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles
Journal of Virology · 23.07.2024 · 98 (7)
DOI: 10.1128/jvi.00681-24 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Virology, erschienen am 23.07.2024. Verfasst von Matthias Lingemann und 4 weiteren Autor:innen. Beteiligte Einrichtung: Arbovirus Vaccine Research Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Healt…. Hauptthemen laut MEDLINE: Antibodies, Neutralizing, Dengue Virus, Antibodies, Viral, Serogroup. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID).
Abstract (Originalsprache)
Serum-neutralizing antibody titers are a critical measure of vaccine immunogenicity and are used to determine flavivirus seroprevalence in study populations. An effective dengue virus (DENV) vaccine must confer simultaneous protection against viruses grouped within four antigenic serotypes. Existing flavivirus neutralization assays, including the commonly used plaque/focus reduction neutralization titer (PRNT/FRNT) assay, require an individual assay for each virus, serotype, and strain and easily become a labor-intensive and time-consuming effort for large epidemiological studies or vaccine trials. Here, we describe a multiplex reporter virus particle neutralization titer (TetraPlex RVPNT) assay for DENV that allows simultaneous quantitative measures of antibody-mediated neutralization of infection against all four DENV serotypes in a single low-volume clinical sample and analyzed by flow cytometry. Comparative studies confirm that the neutralization titers of antibodies measured by the TetraPlex RVPNT assay are similar to FRNT/PRNT assay approaches performed separately for each viral strain. The use of this high-throughput approach enables the careful serological study in DENV endemic populations and vaccine recipients required to support the development of a safe and effective tetravalent DENV vaccine. IMPORTANCE As a mediator of protection against dengue disease and a serological indicator of prior infection, the detection and quantification of neutralizing antibodies against DENV is an important “gold standard” tool. However, execution of traditional neutralizing antibody assays is often cumbersome and requires repeated application for each virus or serotype. The optimized RVPNT assay described here is high-throughput, easily multiplexed across multiple serotypes, and targets reporter viral particles that can be robustly produced for all four DENV serotypes. The use of this transformative RVPNT assay will support the expansion of neutralizing antibody datasets to answer research and public health questions often limited by the more cumbersome neutralizing antibody assays and the need for greater quantities of test serum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arbovirus Vaccine Research Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Translational Immunobiology Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Viral Pathogenesis Section, Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
- Arbovirus Immunology Section, Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
ORCID-Profile: Stephen S Whitehead
Förderung
- HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
Zitieren
APA
Lingemann, M., Amaro-Carambot, E., Lamirande, E. W., Pierson, T. C., & Whitehead, S. S. (2024). Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles. Journal of Virology, 98(7). https://doi.org/10.1128/jvi.00681-24
Vancouver
Lingemann M, Amaro-Carambot E, Lamirande EW, Pierson TC, Whitehead SS. Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles. Journal of Virology. 2024;98(7). doi:10.1128/jvi.00681-24
BibTeX
@article{Lingemann2024,
author = {Lingemann, Matthias and Amaro-Carambot, Emérito and Lamirande, Elaine W and Pierson, Theodore C and Whitehead, Stephen S},
title = {Simultaneous quantitation of neutralizing antibodies against all four dengue virus serotypes using optimized reporter virus particles},
journal = {Journal of Virology},
year = {2024},
volume = {98},
number = {7},
doi = {10.1128/jvi.00681-24}
}
EUVIMED